

Herantis Pharma to Participate in the Upcoming Nordic Life Science Days

Herantis Pharma Plc, Company Release, 13 April 2021 at 08:00 EEST

Herantis Pharma Plc (“Herantis”), focusing on disease modifying therapies for debilitating neurodegenerative diseases, today announced that Dr. Craig Cook, Chief Executive Officer, will hold 1x1 meetings and have a digital company presentation in the upcoming Nordic Life Science Days conference.

Event Details:

Nordic Life Science Days Digital

Dates: 20 – 23 April 2021

On 20 April 2021 all presentations will be available via a digital library, which is accessible to event participants only. Please contact the organizers at the Nordic Life Science Days if you wish to attend.

For more information, please contact:

Julie Silber/Gabriela Urquilla

Tel: +46 (0)7 93 486 277/+46 (0)72-396 72 19

Email: ir@herantis.com

Certified Advisor: UB Securities Ltd, Finland: +358 9 25 380 225, Sweden: +358 40 5161400

Company website: www.herantis.com

About Herantis Pharma Plc

Herantis focuses on disease modifying therapies for debilitating neurodegenerative diseases by restoring the neuronal protective mechanism of proteostasis, a key system in neurodegenerative disease. Proteostasis regulates proteins within the body and influences the fate of every protein from synthesis to degradation. Its failure results in a vicious cycle of pathological accumulation of protein aggregates, neuroinflammation and various forms of cellular stress that is widely implicated with the development of many neurodegenerative diseases including Parkinson’s Disease, Alzheimer’s and other diseases. CDFN is a natural protein that occurs naturally in the body whose natural role is to protect neurons by balancing and supporting proteostasis, thereby preventing and counteracting disease generating mechanisms. Herantis is taking this natural ability and harnessing it as a treatment for neurodegenerative disease. CDFN - a biological protein - is Herantis’ lead program and a clinical stage asset; and xCDFN (a synthetic peptide version of CDFN) is Herantis’ follow-on program. Both CDFN and xCDFN, via their multimodal mechanism of action, have the potential to improve neuronal survival and stop the progression of Parkinson’s and other neurodegenerative diseases with a significant therapeutic impact on the quality of patients’ lives.

The shares of Herantis are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden. For more information, please visit <https://www.herantis.com>